ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0314618 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yibo Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Cheeloo C…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Glioma, RNA, Long Noncoding, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Glioma is the most common intracranial malignancy, and the available treatment options are poor. Long noncoding RNAs (lncRNAs) have been reported to be involved in the malignant progression of glioma. The role of ZNF503-AS2 in glioma has not been reported.
Methods
We screened ZNF503-AS2 with upregulated expression in glioblastoma (GBM) by analyzing the TCGA, CGGA and GTEx databases. Single sample gene set enrichment analysis (ssGSEA) was used to calculate the enrichment of immune cells and signaling pathways in glioma samples. Single-cell datasets were used to analyze the distribution of ZNF503-AS2. In vitro experiments were used to investigate the biological function of ZNF503-AS2.
Results
ZNF503-AS2 was highly expressed in glioma and was associated with poor prognosis, malignant progression and infiltration of immunosuppressive cells. Single-cell transcriptomic analysis showed that ZNF503-AS2 was mainly expressed in macrophages and tumor cells. Further analysis revealed that immunotherapy may have better efficacy in patients with low ZNF503-AS2 expression. In vitro experiments showed that knockdown of ZNF503-AS2 reduced the proliferation, invasion and migration ability of glioma cells, induced G2/M cell cycle arrest and promoted apoptosis.
Conclusions
ZNF503-AS2 might be a valuable biomarker for predicting the prognosis of glioma patients and a potential target for glioma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Function Remodeling, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science,…
- Shandong Key Laboratory of Brain Function Remodelling, Jinan, China.
- Department of Health Care, Jinan Central Hospital, Jinan, China.
- The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Neurosurgery, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
ORCID-Profile: Donghai Wang, Bin Huang, Xingang Li
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wu, Y., Mu, G., Li, F., Sun, Y., Lin, X., Liu, X., Zhao, Z., Han, M., Wang, D., Huang, B., & Li, X. (2024). ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma. PLOS ONE. https://doi.org/10.1371/journal.pone.0314618
Vancouver
Wu Y, Mu G, Li F, Sun Y, Lin X, Liu X, et al. ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma. PLOS ONE. 2024. doi:10.1371/journal.pone.0314618
BibTeX
@article{Wu2024,
author = {Wu, Yibo and Mu, Guangjing and Li, Fang and Sun, Yanfei and Lin, Xiaoying and Liu, Xuemeng and Zhao, Zhimin and Han, Mingzhi and Wang, Donghai and Huang, Bin and Li, Xingang},
title = {ZNF503-AS2 is a promising therapeutic target and is associated with the immune microenvironment in glioma},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0314618}
}
EUVIMED